Vista Current Coverage

All Healthcare/Biotech Articles

CAR-T Pioneer Dr. Grupp Joins Paris Headquartered Cellectis (CLLS)’s CAB

Cellectis S.A. (Euronext Growth: ALCLS; Nasdaq: CLLS), founded in 1999 and headquartered in Paris, France, is a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates...

Fate Therapeutics Reports Q3 2018 Financial Results & Highlights

Fate Therapeutics (Nasdaq: FATE), headquartered in San Diego, CA, is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC)...

Novartis Purchases Endocyte for $2.1 Billion

Novartis, a Swiss pharmaceutical giant, recently purchased the West Lafayette, Indiana-based company Endocyte. The $2.1 billion acquisition will be a large addition to Novartis’s cancer treatment portfolio. Endocyte is currently conducting clinical trials for radiopharmaceuticals that have the potential to be used to treat metastatic...

Spotlight On Breast Cancer Awareness Month

October, while often associated with pumpkin spice, scary movies, and jack-o-lanterns, is also Breast Cancer Awareness Month – a time when pink ribbons abound and the effort to spread awareness about breast cancer is particularly heightened. Increasing breast cancer awareness is critical to continuing the...

San Diego-based Fate Therapeutics Enters Strategic Collaboration with Tokyo’s ONO Pharmaceutical Co.

San Diego-based Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology...